ClinicalTrials.gg
CompletedNCT00143403Updated Sep 28, 2010Results posted

Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer

A Phase 3 interventional study of Irinotecan + 5 FU + folinic acid and Folinic Acid + 5 FU in Colorectal Neoplasms and Liver Neoplasms, sponsored by Pfizer. Completed at 66 sites in 16 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-09-28.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
321
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 200 studies testing irinotecan in Colorectal Neoplasms — 25 open to participants now, 32 under way, 6 of them phase 3. Irinotecan · Colorectal Neoplasms.

Enrollment
14th of 182
321 · median 47
Started
2001
with 11 others
Phase 3
26 of 200
3 open now
Registered
47th of 200
by date
Lead sponsor
4 of 200
Pfizer

Among the 200 studies testing irinotecan in Colorectal Neoplasms, this one is the 14th largest by enrollment of the 182 interventional ones that give a count, is one of 12 that started in 2001, is one of 26 in phase 3, and was the 47th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

25 of the 200 studies testing irinotecan in Colorectal Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

About irinotecan

Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 200 studies testing irinotecan in Colorectal Neoplasms, or all of them as a file.
02

Study summary

To see if Disease Free Survival (DFS) is improved when complete surgical resection of liver metastases (R0) is followed by chemotherapy with CPT-11 and 5-FU/FA as FOLFIRI regimen, compared to 5-FU/FA alone.

03

Conditions studied

  • Colorectal Neoplasms
  • Liver Neoplasms
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven adenocarcinoma of the colon or rectum with complete resection of primary tumour.
  • Complete surgical resection (R0) of the liver (es) within a minimum of 3 weeks, and a maximum of 8 weeks prior to the first study treatment infusion.
  • Exclusively hepatic metastasis (es) : absence of bone, lung and .

Exclusion criteria

Exclusion Criteria:

  • Prior hepatic radiation or resection.
  • Prior radiofrequency ablation or cryoablation Incomplete surgical resection of liver (es).
  • Prior chemotherapy for metastatic disease.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
321 participants (actual)

Study arms

  • Experimental
    1

    Drug: Irinotecan + 5 FU + folinic acid

  • Active comparator
    2

    Drug: Folinic Acid + 5 FU

Interventions

  • DrugIrinotecan + 5 FU + folinic acid

    Drug pages: Irinotecan · Fluorouracil · Leucovorin

    irinotecan 180 mg/m2 folinic acid 400 mg/m2 (DL) followed by 5 FU bolus 400 mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks

  • DrugFolinic Acid + 5 FU

    Drug pages: Leucovorin · Fluorouracil

    folinic acid 400 mg/m2(DL) followed by bolus 5 FU 400mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks

06

What researchers measure

Primary outcomes

  1. Disease Free Survival (DFS)

    time interval between the date of randomization and the earliest date of local, regional or distant relapse, or death due to cancer.

    Time frame: last tumor assessment date or cut-off date, whichever is earlier.

Secondary outcomes

  1. Overall Survival Rates

    Probability of being alive was calculated in a yearly increment.

    Time frame: Median follow-up time (42 months)

07

Results

Posted Jun 1, 2009

Participant flow

study was conducted at 66 centers.

Participant flow — Overall Study
Milestone5-FU/FAIrinotecan + 5-FU/FA
Started160161
Treated153153
Completed125115
Not completed3546
Withdrew: Adverse event38
Withdrew: Death10
Withdrew: Withdrawal by subject312
Withdrew: Relapse157
Withdrew: Protocol violation22
Withdrew: Specified by site49
Withdrew: Randomized not treated78

Outcome measures

PrimaryDisease Free Survival (DFS)

time interval between the date of randomization and the earliest date of local, regional or distant relapse, or death due to cancer.

Time frame:
last tumor assessment date or cut-off date, whichever is earlier.
Reported as:
Median · months
Disease Free Survival (DFS)
months5-FU/FAIrinotecan + 5-FU/FA
Disease Free Survival (DFS)21.6 (14.6 to 30.4)24.7 (18.7 to 38.9)
Statistical analysis
  • 5-FU/FA vs Irinotecan + 5-FU/FA · Hazard ratio (hr): 0.90 · 95% CI 0.67 to 1.20HR: Irinotecan+5-FU/FA / 5-FU/FA
  • 5-FU/FA vs Irinotecan + 5-FU/FA · Log Rank · p = 0.468
SecondaryOverall Survival Rates

Probability of being alive was calculated in a yearly increment.

Time frame:
Median follow-up time (42 months)
Reported as:
Number · survival rate
Overall Survival Rates
survival rate5-FU/FAIrinotecan + 5-FU/FA
12 months0.9610.973
24 months0.8450.881
36 months0.7160.727

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5-FU/FA—15/152 (9.9%)146/152 (96.1%)
Irinotecan + 5-FU/FA—32/154 (20.8%)150/154 (97.4%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
Event5-FU/FAIrinotecan + 5-FU/FA
Diarrhoea NOSGastrointestinal disorders0/1527/154
Deep vein thrombosisVascular disorders1/1525/154
DizzinessNervous system disorders0/1523/154
NeutropeniaBlood and lymphatic system disorders0/1523/154
Abdominal pain NOSGastrointestinal disorders2/1521/154
Intestinal obstruction NOSGastrointestinal disorders2/1520/154
Vomiting NOSGastrointestinal disorders2/1522/154
Chest painGeneral disorders0/1522/154
DehydrationMetabolism and nutrition disorders0/1522/154
Liver abscessInfections and infestations0/1522/154
Most frequent other events
Showing 10 of 38
Most frequent other events
Event5-FU/FAIrinotecan + 5-FU/FA
NauseaGastrointestinal disorders91/152116/154
Diarrhea, NOSGastrointestinal disorders80/15298/154
AlopeciaSkin and subcutaneous tissue disorders28/15269/154
Vomiting, NOSGastrointestinal disorders37/15264/154
NeutropeniaBlood and lymphatic system disorders25/15262/154
AstheniaGeneral disorders48/15253/154
ConstipationGastrointestinal disorders30/15246/154
Abdominal pain, NOSGastrointestinal disorders40/15241/154
StomatitisGastrointestinal disorders40/15234/154
FatigueGeneral disorders28/15234/154

Baseline characteristics

Age Continuous
Age Continuous(years)5-FU/FAIrinotecan + 5-FU/FATotal
Median61 (34 to 76)63 (27 to 75)62 (27 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)5-FU/FAIrinotecan + 5-FU/FATotal
Female5363116.0
Male10090190.0
08

Study locations

66 sites
  • Pfizer Investigational Site
    Gent, 9000, Belgium
  • Pfizer Investigational Site
    Roeselare, 8800, Belgium
  • Pfizer Investigational Site
    Copenhagen, 2100, Denmark
  • Pfizer Investigational Site
    Herlev, DK-2730, Denmark
  • Pfizer Investigational Site
    Odense, DK5000, Denmark
  • Pfizer Investigational Site
    Amiens cedex 1, 80054, France
  • Pfizer Investigational Site
    Avignon, 84000, France
  • Pfizer Investigational Site
    Boulogne Billancourt cedex, France
  • Pfizer Investigational Site
    Clermont-Ferand Cedex 1, 63058, France
  • Pfizer Investigational Site
    Colmar, 68024, France
  • Pfizer Investigational Site
    Grenoble Cedex 09, 38043, France
  • Pfizer Investigational Site
    Marseille Cedex 9, 13273, France
  • Pfizer Investigational Site
    Marseille, 13005, France
  • Pfizer Investigational Site
    Marseille, 13273 CEDEX 09, France
  • Pfizer Investigational Site
    Montpellier Cedex 5, 34295, France
  • Pfizer Investigational Site
    Montpellier, 34298 CEDEX 5, France
  • Pfizer Investigational Site
    Nice, 06031, France
  • Pfizer Investigational Site
    Nimes, 30900, France
  • Pfizer Investigational Site
    Rennes, 35042, France
  • Pfizer Investigational Site
    Strasbourg, 67091, France
  • Pfizer Investigational Site
    Toulouse cedex, 31059, France
  • Pfizer Investigational Site
    Cottbus, 03048, Germany
  • Pfizer Investigational Site
    Dessau, 06847, Germany
  • Pfizer Investigational Site
    Erlangen, 91054, Germany
  • Pfizer Investigational Site
    Hamburg, 20246, Germany
  • Pfizer Investigational Site
    Leipzig, 04103, Germany
  • Pfizer Investigational Site
    Magdeburg, 39104, Germany
  • Pfizer Investigational Site
    Magdeburg, 39120, Germany
  • Pfizer Investigational Site
    Mainz, 55131, Germany
  • Pfizer Investigational Site
    Oldenburg, 26133, Germany
  • Pfizer Investigational Site
    Regensburg, 93042, Germany
  • Pfizer Investigational Site
    Tuebingen, 72076, Germany
  • Pfizer Investigational Site
    Hong Kong, Hong Kong
  • Pfizer Investigational Site
    Haifa, Israel
  • Pfizer Investigational Site
    Petach-Tikva, Israel
  • Pfizer Investigational Site
    Rehovot, 76100, Israel
  • Pfizer Investigational Site
    Tel-Aviv, 64239, Israel
  • Pfizer Investigational Site
    Tel-Hashomer, Israel
  • Pfizer Investigational Site
    Carpi, Modena 41012, Italy
  • Pfizer Investigational Site
    Brescia, 25123, Italy
  • Pfizer Investigational Site
    Latisana, UD, 33053, Italy
  • Pfizer Investigational Site
    Padova, 35100, Italy
  • Pfizer Investigational Site
    Parma, 43100, Italy
  • Pfizer Investigational Site
    Piacenza, 29100, Italy
  • Pfizer Investigational Site
    Reggio Emilia, 42100, Italy
  • Pfizer Investigational Site
    Rozzano (Mi), 20089, Italy
  • Pfizer Investigational Site
    Daegu, 700-721, Korea, Republic of
  • Pfizer Investigational Site
    Goyang, 411764, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 120-753, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 135-710, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 139-240, Korea, Republic of
  • Pfizer Investigational Site
    Porto, 4200, Portugal
  • Pfizer Investigational Site
    Panorama, Cape Town 7500, South Africa
  • Pfizer Investigational Site
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Pfizer Investigational Site
    Santander, Cantabria 39008, Spain
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    Madrid, 28041, Spain
  • Pfizer Investigational Site
    Sevilla, 41014, Spain
  • Pfizer Investigational Site
    Goteborg, 413 45, Sweden
  • Pfizer Investigational Site
    Bern, 3010, Switzerland
  • Pfizer Investigational Site
    Taoyuan, Taiwan
  • Pfizer Investigational Site
    Donetsk, 83092, Ukraine
  • Pfizer Investigational Site
    Kiev, 03922, Ukraine
  • Pfizer Investigational Site
    London, N18 1QX, United Kingdom
  • Pfizer Investigational Site
    Southampton, SO16 6YD, United Kingdom
  • Pfizer Investigational Site
    Surrey, GU2 7XX, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2001, a primary completion of Feb 2008 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2005
First posted
Sep 2, 2005
Start
Dec 2001
Primary completionActual
Feb 2008
CompletionActual
Sep 2009
Results first posted
Jun 1, 2009
Last update
Sep 28, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00143403
Lead sponsor
Pfizer
First posted
Sep 2, 2005
Start date
Dec 2001
Primary completion
Feb 2008
Completion
Sep 2009
Results posted
Jun 1, 2009
Last update
Sep 28, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Irinotecan · Fluorouracil · Leucovorin

Start the discussion